Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?

Hepatology (Baltimore, Md.) - 1 Jan 2012

Beinhardt Sandra, Staettermayer Albert F, Rutter Karoline, Maresch Judith, Scherzer Thomas M, Steindl-Munda Petra, Hofer Harald, Ferenci Peter

Abstract excerpt

UNLABELLED: Pegylated interferon-alpha2/ribavirin (peg-IFN/RBV) is the standard of care (SOC) for patients with chronic hepatitis C (CHC) infection. Currently, direct-acting antiviral agents (DAAs) are evaluated in clinical trials. The aim of this study was to compare baseline characteristics and sustained virologic response (SVR) rates in patients included in clinical trials to those receiving SOC. Medical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Academic Medical Centers
Share to Europe

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Patient Selection

Share to Randomized Controlled Trials as Topic

Share to Selection Bias

Source

Identifiers

PMID: 21932410
DOI: 10.1002/hep.24671

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?PMID 21932410Read ↗

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Semantic proximity Read ↗

Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.Semantic proximity Read ↗

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency.Semantic proximity Read ↗

Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life': a plea in favor of independent postmarketing evaluations.Semantic proximity Read ↗

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.Semantic proximity Read ↗

Host factors determining the efficacy of hepatitis C treatment.Semantic proximity Read ↗

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.Semantic proximity Read ↗

Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study.Semantic proximity Read ↗

Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect.Semantic proximity Read ↗

Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.Semantic proximity Read ↗

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.Semantic proximity Read ↗

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.